Fesoterodine (INN used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007 the US Food and Drug Administration on October 31 2008 and Health Canada on February 9 2012.Fesoterodine is a prodrug. It is broken down into its active metabolite 5-hydroxymethyl tolterodine by plasma esterases.
This page contains content from the copyrighted Wikipedia article "Fesoterodine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
